|
1
|
Rapozzi V, Della Pietra E and Bonavida B:
Dual roles of nitric oxide in the regulation of tumor cell response
and resistance to photodynamic therapy. Redox Biol. 6:311–317.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fukumura D, Kashiwagi S and Jain RK: The
role of nitric oxide in tumour progression. Nat Rev Cancer.
6:521–534. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choudhari SK, Chaudhary M, Bagde S,
Gadbail AR and Joshi V: Nitric oxide and cancer: A review. World J
Surg Oncol. 11:1182013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ambs S and Glynn SA: Candidate pathways
linking inducible nitric oxide synthase to a basal-like
transcription pattern and tumor progression in human breast cancer.
Cell Cycle. 10:619–624. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Switzer CH, Glynn SA, Cheng RY, Ridnour
LA, Green JE, Ambs S and Wink DA: S-nitrosylation of EGFR and Src
activates an oncogenic signaling network in human basal-like breast
cancer. Mol Cancer Res. 10:1203–1215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vannini F, Kashfi K and Nath N: The dual
role of iNOS in cancer. Redox Biol. 6:334–343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu X, Wang ZF, Xu Y, Ren R, Heng BL and Su
ZX: Association between three eNOS polymorphisms and cancer risk: A
meta-analysis. Asian Pac J Cancer Prev. 15:5317–5324. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Broholm H, Rubin I, Kruse A, Braendstrup
O, Schmidt K, Skriver EB and Lauritzen M: Nitric oxide synthase
expression and enzymatic activity in human brain tumors. Clin
Neuropathol. 22:273–281. 2003.PubMed/NCBI
|
|
9
|
Ambs S, Bennett WP, Merriam WG, Ogunfusika
MO, Oser SM, Khan MA, Jones RT and Harris CC: Vascular endothelial
growth factor and nitric oxide synthase expression in human lung
cancer and the relation to p53. Br J Cancer. 78:233–239. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Y, Zhou R, Sulman EP, Scheurer ME,
Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad
CA, et al: Genetic modulation of neurocognitive function in glioma
patients. Clin Cancer Res. 21:3340–3346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kotake M, Sato K, Mogi C, Tobo M, Aoki H,
Ishizuka T, Sunaga N, Imai H, Kaira K, Hisada T, et al: Acidic pH
increases cGMP accumulation through the OGR1/phospholipase
C/Ca(2+)/neuronal NOS pathway in N1E-115 neuronal cells. Cell
Signal. 26:2326–2332. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Q, Tomei S, Ascierto ML, De Giorgi V,
Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J, et al:
Melanoma NOS1 expression promotes dysfunctional IFN signaling. J
Clin Invest. 124:2147–2159. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hamaoka R, Yaginuma Y, Takahashi T, Fujii
J, Koizumi M, Seo HG, Hatanaka Y, Hashizume K, Ii K, Miyagawa J, et
al: Different expression patterns of nitric oxide synthase isozymes
in various gynecological cancers. J Cancer Res Clin Oncol.
125:321–326. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thomsen LL, Sargent JM, Williamson CJ and
Elgie AW: Nitric oxide synthase activity in fresh cells from
ovarian tumour tissue: Relationship of enzyme activity with
clinical parameters of patients with ovarian cancer. Biochem
Pharmacol. 56:1365–1370. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Caneba CA, Yang L, Baddour J, Curtis R,
Win J, Hartig S, Marini J and Nagrath D: Nitric oxide is a positive
regulator of the Warburg effect in ovarian cancer cells. Cell Death
Dis. 5:e13022014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leung EL, Fraser M, Fiscus RR and Tsang
BK: Cisplatin alters nitric oxide synthase levels in human ovarian
cancer cells: Involvement in p53 regulation and cisplatin
resistance. Br J Cancer. 98:1803–1809. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lawrie TA, Winter-Roach BA, Heus P and
Kitchener HC: Adjuvant (post-surgery) chemotherapy for early stage
epithelial ovarian cancer. Cochrane Database Syst Rev.
12:CD0047062015.
|
|
19
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park B, Park S, Kim TJ, Ma SH, Kim BG, Kim
YM, Kim JW, Kang S, Kim J, Kim TJ, et al: Epidemiological
characteristics of ovarian cancer in Korea. J Gynecol Oncol.
21:241–247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goff BA, Mandel L, Muntz HG and Melancon
CH: Ovarian carcinoma diagnosis. Cancer. 89:2068–2075. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vasudevan D and Thomas DD: Insights into
the diverse effects of nitric oxide on tumor biology. Vitam Horm.
96:265–298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Apps MG, Choi EH and Wheate NJ: The
state-of-play and future of platinum drugs. Endocr Relat Cancer.
22:R219–R233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
